|
Age (years), mean ± SD
|
61 ± 11
|
60 ± 10
|
59 ± 11
|
58 ± 13
|
0.2908
|
|
Gender Male n (%)
|
256 (53)
|
24 (47)
|
28 (62)
|
14 (78)
|
0.0866
|
|
BMI (kg/m2) n (%)
|
|
≥ 30
|
74 (15)
|
10 (20)
|
7 (16)
|
2 (11)
|
0.9531
|
|
< 18.5
|
12 (2)
|
2 (4)
|
0 (0)
|
0 (0)
|
|
[25–30[
|
163 (34)
|
14 (27)
|
17 (38)
|
7 (39)
|
|
[18.5–25[
|
233 (48)
|
25 (49)
|
21 (47)
|
9 (50)
|
|
Chronic hepatitis duration (years), mean ± SD
|
16 ± 8
|
15 ± 7
|
16 ± 9
|
11 ± 8
|
0.0814
|
|
HCV genotype n (%)
|
|
1a
|
110 (23)
|
11 (22)
|
14 (31)
|
6 (33)
|
0.2543
|
|
4
|
99 (20)
|
17 (33)
|
10 (22)
|
6 (33)
|
|
1 not subtyped
|
25 (5)
|
1 (2)
|
3 (7)
|
0 (0)
|
|
1b
|
251 (52)
|
22 (43)
|
18 (40)
|
6 (33)
|
|
Diabetes n (%)
|
104 (21)
|
7 (14)
|
9 (20)
|
1 (6)
|
0.2710
|
|
Hypertension n (%)
|
194 (40)
|
25 (49)
|
18 (40)
|
4 (22)
|
0.2571
|
|
Cirrhosis n (%)
|
259 (54)
|
33 (65)
|
27 (60)
|
16 (89)
|
0.0117
|
|
•Child-Pugh score B or C
|
17 (7)
|
8 (24)
|
1 (4)
|
2 (13)
|
0.0083
|
|
•MELD ≥15
|
19 (8)
|
4 (13)
|
1 (4)
|
3 (19)
|
0.2444
|
|
•Elastography ≥14.5 kPa
|
131 (51)
|
15 (45)
|
14 (52)
|
10 (63)
|
0.7540
|
|
•Fibrotest ≥0.73
|
70 (27)
|
10 (30)
|
11 (41)
|
10 (63)
|
0.0175
|
|
•Liver biopsy > 2 years
|
148 (57)
|
20 (61)
|
14 (52)
|
7 (44)
|
0.6618
|
|
•Liver biopsy < 2 years
|
18 (7)
|
2 (6)
|
1 (4)
|
0 (0)
|
0.9306
|
|
Decompensated cirrhosis n (%)
|
16 (3)
|
6 (12)
|
2 (4)
|
0 (0)
|
0.0483
|
|
•Child-Pugh score B or C
|
6 (38)
|
4 (67)
|
1 (50)
| |
0.5589
|
|
•MELD score, mean ± SD
|
9.7 ± 2.9
|
12.3 ± 3.9
|
12.5 ± 0.7
| |
0.1793
|
|
Albumin (< 30 g/L) n (%)
|
12 (3)
|
5 (11)
|
1 (3)
|
1 (6)
|
0.0415
|
|
Prothrombin time (≤70%) n (%)
|
45 (10)
|
11 (22)
|
6 (14)
|
6 (33)
|
0.0037
|
|
AST (> 5 x ULN) n (%)
|
28 (6)
|
4 (8)
|
3 (7)
|
2 (12)
|
0.4951
|
|
ALT (> 5 x ULN) n (%)
|
31 (6)
|
2 (4)
|
1 (2)
|
1 (6)
|
0.7735
|
|
Haemoglobin (≤12 g/dL in women or ≤ 13 g/dL in men) n (%)
|
58 (12)
|
8 (16)
|
5 (11)
|
1 (6)
|
0.7365
|
|
Platelets < 100,000/mm3
|
87 (19)
|
15 (30)
|
11 (25)
|
8 (47)
|
0.0109
|
|
Bilirubin conj ≥5 μmol/L
|
133 (52)
|
20 (63)
|
16 (57)
|
13 (100)
|
0.0021
|
|
Treatment history n (%)
|
|
•Naïve patients
|
141 (29)
|
13 (25)
|
14 (31)
|
5 (28)
|
0.0618
|
|
•Experienced patients, last treatment PEG/RBV
|
324 (67)
|
35 (69)
|
25 (56)
|
10 (56)
|
|
•Experienced patients, last treatment 1rst generation PI/PEG/RBV
|
20 (4)
|
3 (6)
|
6 (13)
|
3 (17)
|
|
Response profile in treatment experienced patients
|
|
•Unknown
|
164 (48)
|
20 (53)
|
17 (55)
|
6 (46)
|
0.8370
|
|
•Responders
|
86 (25)
|
9 (24)
|
4 (13)
|
3 (23)
|
|
•Not responders
|
94 (27)
|
9 (24)
|
10 (32)
|
4 (31)
|
